Article

Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia – a proof-of- concept study

2022-03-07

Abstract excerpt

Risk-adapted treatment in acute lymphoblastic leukemia (ALL) relies on genetic information and measurable residual disease (MRD) monitoring. In this proof-of-concept study, DNA from diagnostic bone marrow from six children with ALL, without stratifying genetics or CNS involvement, underwent whole-genome sequencing to identify structural variants (SVs) in the leukemic blasts. Unique sequences generated by SVs were...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 659998bd-5457-5843-a4ff-c149eff3f06b
DOI: 10.21203/rs.3.rs-1403708/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia – a proof-of- concept studyDOI 10.21203/rs.3.rs-1403708/v1Read

Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid LeukemiaSemantic proximity Read

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic LeukemiaSemantic proximity Read

Digital droplet PCR and next-generation sequencing refine minimal residual disease monitoring in acute lymphoblastic leukemiaSemantic proximity Read

Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma.Semantic proximity Read

Simultaneous Ultra-Sensitive Detection of Structural and Single Nucleotide Variants Using Multiplex Droplet Digital PCR in Liquid Biopsies from Children with MedulloblastomaSemantic proximity Read

Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic LeukemiaSemantic proximity Read

Identification and Use of Personalized Genomic Markers for Monitoring Circulating Tumor DNA.Semantic proximity Read

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?Semantic proximity Read

Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine.Semantic proximity Read

Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept studySemantic proximity Read

Double Drop-Off Droplet Digital PCR: A Novel, Versatile Tool for Mutation Screening and Residual Disease Monitoring in Acute Myeloid Leukemia Using Cellular or Cell-Free DNA.Semantic proximity Read

A New View on Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia using Droplet Digital PCRSemantic proximity Read